Form 4 for GALT GALECTIN THERAPEUTICS INC
Accepted 2023-01-30 00:00:00 ET · period of report 2023-01-26 · accession 0001133416-23-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-30 | 2023-01-26 | GALT | Uihlein Richard E | Dir, 10% | A - Grant | $1.11 | +36.0K | 8.00M | +0.5% | +$40.0K |
| D | 2023-01-30 | 2023-01-26 | GALT | Uihlein Richard E | Dir, 10% | A - Grant | $0.00 | +40.0K | 40.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-26 | A | A | 36,036 | $1.11 | 7,999,291 | D | — | — | (F1) These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2023. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2023. |
| 2 | Derivative | Stock Option (right to buy) | 2023-01-26 | A | A | 40,000 | $0.00 | 40,000 | D | $1.11 · — to 2033-01-26 | 40,000 Common Stock | (F3) The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. (F4) The options vest 100% on December 31, 2023. |